An aspirin a day may keep melanoma at bay, a new study suggests.
After scrutinizing the medical records of 1,000 people, an international team of researchers have determined that the risk of melanoma was cut by almost half when people took a daily dose of aspirin for at least five years.
“Our data at least support the hypothesis that long-term steady aspirin use has an effect,” said study co-author Dr. Robert Stern, a professor of dermatology at Harvard Medical School and chief of dermatology at Beth Israel Deaconess Hospital in Boston.
Previously, the only melanoma prevention advice cancer experts could give was for people to stay out of the sun and get their skin checked for early warning signs of the disease. If melanoma isn’t detected early, it can be deadly.
Stern and his colleagues compared data from 400 melanoma patients to that from 600 healthy volunteers. The healthy volunteers were matched in age and gender to the cancer patients, some of whom ended up with more than one matched group.
The 1,000 study participants were interviewed and asked about lifestyle habits and known risk factors for melanoma, such as light skin color and history of sunburns. They were also questioned about medication use.
While melanoma is not as common as other types of skin cancer, it is the most dangerous and most likely to spread to other parts of the body. It killed nearly 9,000 people in the U.S. last year, according to the National Cancer Institute.
The researchers focused on usage of anti-cholesterol statins and nonsteroidal anti-inflammatory medications, or NSAIDs, because some earlier population studies had suggested that these medications might have an impact on melanoma development.
Although the study found no beneficial effect associated with statin use, it did find a substantial reduction in risk associated with the use of aspirin, which is an anti-inflammatory. There was also a hint that other NSAIDs, such as ibuprofen (marketed as Advil and Motrin) and naproxen (Aleve), might reduce melanoma risk if taken regularly over a long period of time. But the data on these drugs wasn’t as strong.
Stern suspects that may be because far fewer people take these NSAIDs on a daily basis. Many middle-aged people take a daily baby aspirin to protect their hearts, he said. The use of other NSAID painkillers tends to be more sporadic.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
Melanoma isn’t the only cancer that appears to be affected by NSAIDs. Other research has shown that the medications can lower the risk of colorectal cancer .
Nobody knows why NSAIDs might prevent cancer, but there are theories. Some researchers suspect that cancers like melanoma hijack the body’s inflammatory response to a growing tumor to bring more blood to the site and to help cancer cells slip past the body’s defenses and attach elsewhere, said Dr. John Kirkwood, director of the Melanoma Center at the University of Pittsburgh.
Kirkwood hopes that the new study will spur researchers to do a long-term study to look at the impact of NSAIDs prospectively, since the protective effect seen here might not be the result of the medication, but rather something that people who take daily aspirin have in common.
Until that happens, doctors can’t counsel patients to take aspirin to protect against melanoma. Still, this is one more possible benefit to consider if you’re advised to take aspirin to prevent heart disease, he said.
For now, this is the first piece of good news on the melanoma prevention front.
“The hope,” Kirkwood said, “is to stop the disease before it gets out of the starting blocks.”Story: New drugs help melanoma patients live longer
Linda Carroll is a health and science writer living in New Jersey. Her work has appeared in The New York Times, Newsday, Health magazine and SmartMoney. She is co-author of the forthcoming book, "The Concussion Crisis: Anatomy of a Silent Epidemic."
© 2013 msnbc.com. Reprints